Systemic immunoglobulin light chain (AL) amyloidosis is a heterogeneous rare disease
driven by a destructive monoclonal gammopathy and typified by misfolded immunoglobulin …

Immunoglobulin light chain (AL) amyloidosis is a rare hematologic disorder characterized by
end-organ damage from deposition of fibrillar aggregates of kinetically unstable light chains …

Background In light-chain (AL) amyloidosis, whether functional status and heart failure–
related quality of life (HF-QOL) correlate with cardiomyopathy severity, improve with therapy …

Immunoglobin light chain (AL) amyloidosis is a rare disease in which a plasma cell
dyscrasia leads to deposition of insoluble amyloid fibrils in multiple organs. To facilitate …

Immunoglobulin light chain (AL) amyloidosis is a malignant plasma cell dyscrasia causing
multi-organ morbidity. High dose melphalan and autologous stem cell transplantation …

Conclusion Given rapid evolution of natural history in ATTR amyloidosis, the utility of
historical control data is limited. Leveraging contemporary real-world data is essential for …

Objective To assess the impact of organ involvement on patient‐reported outcomes (PROs)
in light chain (AL) amyloidosis. Methods PROs were evaluated using the KCCQ‐12 …

Objective To evaluate the psychometric properties of the AL‐PROfile, a patient‐reported
outcome measure combining the Patient‐Reported Outcomes Measurement Information …

Immunoglobin light chain (AL) amyloidosis is a rare disease characterized by organ
deposition of amyloid fibrils, most commonly in the heart and kidney. Disease heterogeneity …

Initiatives to share assets in the life science sector through dedicated partnerships had and
still have a multitude of different aspects in the past few decades. The range goes from …